# A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Study · id `cardio:ct-nct05171049` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05171049](<https://clinicaltrials.gov/study/NCT05171049>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05171049

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1150 participants.

## Technical summary

Registry record NCT05171049. Randomized; single masking; primary purpose treatment. Start 2022-05-05 (actual); primary completion 2026-02-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1150 participants (enrolled count; ClinicalTrials.gov record NCT05171049, source copy `cardio:ctgov-nct05171049-2026-02-23`, retrieved 2026-10-31)
- Started: 2022-05-05 (actual) (ClinicalTrials.gov record NCT05171049, source copy `cardio:ctgov-nct05171049-2026-02-23`, retrieved 2026-10-31)
- Primary completion: 2026-02-04 (actual) (ClinicalTrials.gov record NCT05171049, source copy `cardio:ctgov-nct05171049-2026-02-23`, retrieved 2026-10-31)
- Completion: 2026-02-04 (actual) (ClinicalTrials.gov record NCT05171049, source copy `cardio:ctgov-nct05171049-2026-02-23`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Canada; China; Czechia; France; Germany; Hungary; Ireland; Italy; Japan; Latvia; Netherlands; Norway; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT05171049, source copy `cardio:ctgov-nct05171049-2026-02-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05171049-2026-02-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- Acronym: ASTER
- Condition: Venous Thromboembolism
- Condition: Deep Venous Thrombosis
- Condition: Pulmonary Embolism
- Intervention (Biological): Abelacimab
- Intervention (Drug): Apixaban
- Lead sponsor: Anthos Therapeutics, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Novartis Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Anthos Therapeutics, Inc. (`cardio:org-anthos-therapeutics-inc`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

## Provenance

Content hash: 736283419e02e467e8a6bb3e44ca0cc2ddf9678fd0412fafc0d0e65f532fdaa5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
